| [1] |
Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries[J]. CA Cancer J Clin, 2026, 76(4): e70090.
|
| [2] |
孙可欣, 李荔, 王少明, 等. 2024年中国分地区恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2026, 48(3): 400-412.
|
| [3] |
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841[J]. J Clin Oncol, 2012, 30(3): 263-267.
|
| [4] |
Foster JM, Zhang C, Rehman S, et al. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future[J]. CA Cancer J Clin, 2023, 73(1): 49-71.
|
| [5] |
Bootsma S, Dings MPG, Kesselaar J, et al. Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases[J]. Cell Rep Med, 2024, 5(5): 101523.
|
| [6] |
Bhat AA, Nisar S, Singh M, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy[J]. Cancer Commun (Lond), 2022, 42(8): 689-715.
|
| [7] |
Rietveld PCS, Guchelaar NaD, Sassen SDT, et al. A clinical pharmacological perspective on intraperitoneal chemotherapy[J]. Drugs, 2025, 85(7): 931-943.
|
| [8] |
Pan S, Yuan H, Zhai Q, et al. The journey of nanoparticles in the abdominal cavity: exploring their in vivo fate and impact factors[J]. J Control Release, 2024, 376: 266-285.
|
| [9] |
Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications[J]. Lancet Oncol, 2019, 20(7): e368-e377.
|
| [10] |
Reymond MA, Holthaus K, Wiebke S. Giving patients more good days: the promise of pessurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis[J]. Eur J Surg Oncol, 2026, 52(1): 111206.
|
| [11] |
Guchelaar NaD, Noordman BJ, Koolen SLW, et al. Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies[J]. Drugs, 2023, 83(2): 159-180.
|
| [12] |
Robella M, Vitturini M, Di Giorgio A, et al. Advances in bidirectional therapy for peritoneal metastases: a systematic review of pressurized intraperitoneal aerosol chemotherapy (PIPAC) combined with systemic chemotherapy[J]. Cancers (Basel), 2025, 17(15): 2580.
|
| [13] |
Lurvink RJ, Rovers KP, Nienhuijs SW, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review[J]. J Gastrointest Oncol, 2021, 12(Suppl. 1): s242-s258.
|
| [14] |
Sleiman MJ, Jelip A, Buchs N, et al. Pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a systematic review of the evidence[J]. Cancers (Basel), 2024, 16(21): 3661.
|
| [15] |
徐璐, 孙婧. 结直肠癌伴腹膜转移治疗的研究进展[J]. 临床肿瘤学杂志, 2023, 28(1): 84-89.
|
| [16] |
黄莹莹, 赵赟博. 腹膜转移癌内科治疗新进展[J]. 中国肿瘤临床, 2020, 47(3): 123-127.
|
| [17] |
Baggaley AE, Lafaurie G, Tate SJ, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework[J]. Br J Surg, 2022, 110(1): 10-18.
|
| [18] |
Perelló-Trias MT, Serrano-Muñoz AJ, Rodríguez-Fernández A, et al. Intraperitoneal drug delivery systems for peritoneal carcinomatosis: bridging the gap between research and clinical implementation[J]. J Control Release, 2024, 373: 70-92.
|
| [19] |
Raoof M, Whelan RL, Sullivan KM, et al. Safety and efficacy of oxaliplatin pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in colorectal and appendiceal cancer with peritoneal metastases: results of a multicenter phase I trial in the USA[J]. Ann Surg Oncol, 2023, 30(12): 7814-7824.
|
| [20] |
Kyle P, Perry K, Moutadjer A, et al. UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) with oxaliplatin for colorectal cancer peritoneal metastases (NCT03868228)[J]. Pleura Peritoneum, 2023, 8(4): 157-165.
|
| [21] |
De Bree E, Michelakis D, Stamatiou D, et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy[J]. Pleura Peritoneum, 2017, 2(2): 47-62.
|
| [22] |
So JBY. Bi-directional chemotherapy for peritoneal metastases[J]. Br J Surg, 2023, 110(6): 627-628.
|
| [23] |
Graversen M, Detlefsen S, Ainsworth AP, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study[J]. Ann Surg Oncol, 2023, 30(5): 2634-2644.
|
| [24] |
Marrelli D, Carbone L, Fusario D, et al. Pressurized intra-peritoneal aerosol chemotherapy (PIPAC) for peritoneal malignancies with palliative and bidirectional intent[J]. Cancers (Basel), 2025, 17(12): 1938.
|
| [25] |
Catania G, Zilio S, Bakrin N, et al. Immunomodulatory intraperitoneal chemotherapy with DACHPt-loaded biomaterial nanoparticles in colorectal carcinomatosis[J]. Pharmacol Res, 2025, 222: 108035.
|
| [26] |
Kovalyk X, Saniternik S, Hamacher LM, et al. Gelatin and collagen-mimetic nanoparticles for intraperitoneal cisplatin delivery: from synthesis to in-vivo SPECT imaging of biodistribution[J]. Biomater Adv, 2026, 180: 214601.
|
| [27] |
Constantinides A, Lansu N, Mosen P, et al. Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade[J]. Transl Oncol, 2025, 59: 102464.
|
| [28] |
Siebert M, Alyami M, Mercier F, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. a single center comparative study[J]. Eur J Surg Oncol, 2021, 47(1): 139-142.
|
| [29] |
Mirnezami R, Mehta AM, Chandrakumaran K, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone[J]. Br J Cancer, 2014, 111(8): 1500-1508.
|
| [30] |
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin[J]. J Clin Oncol, 2009, 27(5): 681-685.
|
| [31] |
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study[J]. Cancer, 2000, 88(2): 358-363.
|
| [32] |
Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study[J]. Lancet Oncol, 2015, 16(13): 1306-1315.
|
| [33] |
Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 256-266.
|
| [34] |
Lundbech M, Krag AE, Iversen LH, et al. Elevated thrombin generation and venous thromboembolism incidence in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy compared with minimally invasive rectal surgery[J]. Thromb Haemost, 2025, 125(5): 460-469.
|
| [35] |
Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study[J]. J Clin Oncol, 2010, 28(1): 63-68.
|
| [36] |
Aulicino M, Santullo F, D’annibale G, et al. Efficacy and insights from an extensive series of cytoreductive surgery for peritoneal neoplasms: a high-volume single-center experience[J]. Cancers (Basel), 2024, 16(24): 4229.
|
| [37] |
Girshally R, Demtröder C, Albayrak N, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. World J Surg Oncol, 2016, 14(1): 253.
|
| [38] |
Alyami M, Mercier F, Siebert M, et al. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Eur J Surg Oncol, 2021, 47(1): 128-133.
|
| [39] |
Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study[J]. J Clin Oncol, 2004, 22(16): 3284-3292.
|
| [40] |
Tabchouri N, Buggisch J, Demtröder CR, et al. Pressurized intraperitoneal aerosol chemotherapy for colorectal peritoneal metastases[J]. Ann Surg Oncol, 2021, 28(9): 5275-5286.
|
| [41] |
Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J]. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
|
| [42] |
Jørgensen MS, Ainsworth AP, Fristrup CW, et al. Prognostic value of baseline peritoneal fluid cytology in 224 patients with unresectable peritoneal metastasis treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC)[J]. Hum Pathol, 2025, 168: 106017.
|
| [43] |
Roensholdt S, Graversen M, Detlefsen S, et al. The role of inflammatory biomarkers in PIPAC: predicting survival and treatment completion in patients with peritoneal metastasis[J]. J Cancer, 2026, 17(1): 10-20.
|
| [44] |
Van De Vlasakker VCJ, Rauwerdink P, Rovers KPB, et al. Patient-reported outcomes during first-line palliative systemic therapy alternated with pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-Ⅱ)[J]. Surg Endosc, 2024, 38(11): 6566-6576.
|
| [45] |
Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized Intra Peritoneal Aerosol Chemotherapy (PIPAC)[J]. Eur J Surg Oncol, 2015, 41(10): 1379-1385.
|
| [46] |
Kryh-Jensen CG, Fristrup CW, Ainsworth AP, et al. What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC)[J]. Pleura Peritoneum, 2023, 8(4): 147-155.
|
| [47] |
Lurvink RJ, Rovers KP, Wassenaar ECE, et al. Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)[J]. Surg Endosc, 2022, 36(6): 4486-4498.
|
| [48] |
Van De Vlasakker VCJ, Lurvink RJ, Wassenaar EC, et al. Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery[J]. Sci Rep, 2023, 13(1): 20458.
|
| [49] |
《加压腹腔气溶胶化疗技术及操作规范与职业防护》编审委员会. 加压腹腔气溶胶化疗技术及操作规范与职业防护建议(2026版)[J]. 中华胃肠外科杂志, 2026, 29(4): 393-408.
|
| [50] |
刘磊, 胡烨婷, 孔祥兴, 等. 结直肠癌腹膜转移转化治疗策略与手术时机选择[J]. 中华胃肠外科杂志, 2026, 29(5): 636-647.
|
| [51] |
Tozzi F, Rashidian N, Ceelen W, et al. Standardizing eligibility and patient selection for pressurized intraperitoneal aerosol chemotherapy: a Delphi consensus statement[J]. Eur J Surg Oncol, 2024, 50(6): 108346.
|